CC chemokine receptor 8 (CCR8) belongs to the class A of G protein-coupled receptor. It is highly expressed on Treg and T helper 2 (TH2) cells recruited to the inflammation site and is implicated in allergy and asthma. Recently, CCR8+Treg cells have been suggested to be a master regulator in the immunosuppressive tumor microenvironment; therefore, developing sensitive monoclonal antibodies (mAbs) for CCR8 has been desired. This study established a specific and sensitive mAb for mouse CCR8 (mCCR8), which is useful for flow cytometry by using the Cell-Based Immunization and Screening (CBIS) method. The established anti-mCCR8 mAb, C8Mab-2 (rat IgG2b, kappa), reacted with mCCR8-overexpressed Chinese hamster ovary-K1 (CHO/mCCR8) cells and P388 (mouse lymphoid neoplasma) or J774-1 (mouse macrophage-like) cells, which express endogenous mCCR8 by flow cytometry. C8Mab-2, which was established by the CBIS method, could be useful for elucidating the mCCR8-related biological response by flow cytometry.
Get full access to this article
View all access options for this article.
References
1.
DemariaO, CornenS, DaeronM, MorelY, MedzhitovR, and VivierE: Harnessing innate immunity in cancer therapy. Nature, 2019; 574:45–56.
2.
OhueY, and NishikawaH: Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?. Cancer Sci, 2019; 110:2080–2089.
3.
KarinN: Chemokines and cancer: New immune checkpoints for cancer therapy. Curr Opin Immunol, 2018; 51:140–145.
4.
MartensA, Wistuba-HamprechtK, Geukes FoppenM, YuanJ, PostowMA, WongP, RomanoE, KhammariA, DrenoB, CaponeM, AsciertoPA, Di GiacomoAM, MaioM, SchillingB, SuckerA, SchadendorfD, HasselJC, EigentlerTK, MartusP, WolchokJD, BlankC, PawelecG, GarbeC, and WeideB: Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res, 2016; 22:2908–2918.
5.
YanoH, AndrewsLP, WorkmanCJ, VignaliDAA: Intratumoral regulatory T cells: Markers, subsets and their impact on anti-tumor immunity. Immunology, 2019; 157:232–247.
6.
BianchiniR, KaragiannisSN, JordakievaG, and Jensen-JarolimE: The role of IgG4 in the fine tuning of tolerance in IgE-mediated allergy and cancer. Int J Mol Sci, 2020; 21:5017.
7.
TanakaA, and SakaguchiS: Regulatory T cells in cancer immunotherapy. Cell Res, 2017; 27:109–118.
8.
CurielTJ, CoukosG, ZouL, AlvarezX, ChengP, MottramP, Evdemon-HoganM, Conejo-GarciaJR, ZhangL, BurowM, ZhuY, WeiS, KryczekI, DanielB, GordonA, MyersL, LacknerA, DisisML, KnutsonKL, ChenL, and ZouW: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 2004; 10:942–949.
9.
BarsheshetY, WildbaumG, LevyE, VitenshteinA, AkinseyeC, GriggsJ, LiraSA, and KarinN: CCR8(+)FOXp3(+) Treg cells as master drivers of immune regulation. Proc Natl Acad Sci U S A, 2017; 114:6086–6091.
10.
ChensueSW, LukacsNW, YangTY, ShangX, FraitKA, KunkelSL, KungT, WiekowskiMT, HedrickJA, CookDN, ZingoniA, NarulaSK, ZlotnikA, BarratFJ, O'GarraA, NapolitanoM, and LiraSA: Aberrant in vivo T helper type 2 cell response and impaired eosinophil recruitment in CC chemokine receptor 8 knockout mice. J Exp Med, 2001; 193:573–584.
11.
MikhakZ, FukuiM, FarsidjaniA, MedoffBD, TagerAM, and LusterAD: Contribution of CCR4 and CCR8 to antigen-specific T(H)2 cell trafficking in allergic pulmonary inflammation. J Allergy Clin Immunol, 2009; 123:67–73.e63.
12.
SolerD, ChapmanTR, PoissonLR, WangL, Cote-SierraJ, RyanM, McDonaldA, BadolaS, FedykE, CoyleAJ, HodgeMR, and KolbeckR: CCR8 expression identifies CD4 memory T cells enriched for FOXP3+ regulatory and Th2 effector lymphocytes. J Immunol, 2006; 177:6940–6951.
13.
CoghillJM, FowlerKA, WestML, FultonLM, van DeventerH, McKinnonKP, VincentBG, LinK, Panoskaltsis-MortariA, CookDN, BlazarBR, and SerodyJS: CC chemokine receptor 8 potentiates donor Treg survival and is critical for the prevention of murine graft-versus-host disease. Blood, 2013; 122:825–836.
14.
IellemA, MarianiM, LangR, RecaldeH, Panina-BordignonP, SinigagliaF, and D'AmbrosioD: Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med, 2001; 194:847–853.
15.
PlitasG, KonopackiC, WuK, BosPD, MorrowM, PutintsevaEV, ChudakovDM, and RudenskyAY: Regulatory T cells exhibit distinct features in human breast cancer. Immunity, 2016; 45:1122–1134.
16.
De SimoneM, ArrigoniA, RossettiG, GruarinP, RanzaniV, PolitanoC, BonnalRJP, ProvasiE, SarnicolaML, PanzeriI, MoroM, CrostiM, MazzaraS, VairaV, BosariS, PalleschiA, SantambrogioL, BovoG, ZucchiniN, TotisM, GianottiL, CesanaG, PeregoRA, MaroniN, Pisani CerettiA, OpocherE, De FrancescoR, GeginatJ, StunnenbergHG, AbrignaniS, and PaganiM: Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity, 2016; 45:1135–1147.
17.
WangL, SimonsDL, LuX, TuTY, SolomonS, WangR, RosarioA, AvalosC, SchmolzeD, YimJ, WaismanJ, and LeePP: Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer. Nat Immunol, 2019; 20:1220–1230.
18.
LiyanageUK, MooreTT, JooHG, TanakaY, HerrmannV, DohertyG, DrebinJA, StrasbergSM, EberleinTJ, GoedegebuurePS, and LinehanDC: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol, 2002; 169:2756–2761.
19.
GoyaI, GutiérrezJ, VaronaR, KremerL, ZaballosA, and MárquezG: Identification of CCR8 as the specific receptor for the human beta-chemokine I-309: Cloning and molecular characterization of murine CCR8 as the receptor for TCA-3. J Immunol, 1998; 160:1975–1981.
20.
HoelzingerDB, SmithSE, MirzaN, DominguezAL, ManriqueSZ, and LustgartenJ: Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses. J Immunol, 2010; 184:6833–6842.
21.
LiZ, ChanK, QiY, LuL, NingF, WuM, WangH, WangY, CaiS, and DuJ: Participation of CCL1 in snail-positive fibroblasts in colorectal cancer contribute to 5-fluorouracil/paclitaxel chemoresistance. Cancer Res Treat, 2018; 50:894–907.
22.
KorbeckiJ, GrochansS, GutowskaI, BarczakK, and Baranowska-BosiackaI: CC chemokines in a tumor: A review of pro-cancer and anti-cancer properties of receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands. Int J Mol Sci, 2020; 21:7619.
23.
BernardiniG, SpinettiG, RibattiD, CamardaG, MorbidelliL, ZicheM, SantoniA, CapogrossiMC, and NapolitanoM: I-309 binds to and activates endothelial cell functions and acts as an angiogenic molecule in vivo. Blood, 2000; 96:4039–4045.
24.
DasS, SarrouE, PodgrabinskaS, CassellaM, MungamuriSK, FeirtN, GordonR, NagiCS, WangY, EntenbergD, CondeelisJ, and SkobeM: Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses. J Exp Med, 2013; 210:1509–1528.
25.
VillarrealDO, L'HuillierA, ArmingtonS, MottersheadC, FilippovaEV, CoderBD, PetitRG, and PrinciottaMF: Targeting CCR8 induces protective antitumor immunity and enhances vaccine-induced responses in colon cancer. Cancer Res, 2018; 78:5340–5348.
26.
ItaiS, FujiiY, NakamuraT, ChangYW, YanakaM, SaidohN, HandaS, SuzukiH, HaradaH, YamadaS, KanekoMK, and KatoY: Establishment of CMab-43, a sensitive and specific Anti-CD133 monoclonal antibody, for immunohistochemistry. Monoclon Antib Immunodiagn Immunother, 2017; 36:231–235.
27.
YamadaS, ItaiS, NakamuraT, YanakaM, ChangYW, SuzukiH, KanekoMK, and KatoY: Monoclonal antibody L(1)Mab-13 detected human PD-L1 in lung cancers. Monoclon Antib Immunodiagn Immunother, 2018; 37:110–115.
28.
YamadaS, ItaiS, NakamuraT, YanakaM, KanekoMK, and KatoY: Detection of high CD44 expression in oral cancers using the novel monoclonal antibody, C(44)Mab-5. Biochem Biophys Rep, 2018; 14:64–68.
29.
SchönebergT, and LiebscherI: Mutations in G protein-coupled receptors: Mechanisms, pathophysiology and potential therapeutic approaches. Pharmacol Rev, 2021; 73:89–119.
Vila-CaballerM, González-GranadoJM, ZoritaV, Abu NabahYN, Silvestre-RoigC, Del Monte-MongeA, Molina-SánchezP, Ait-OufellaH, Andrés-ManzanoMJ, SanzMJ, WeberC, KremerL, GutiérrezJ, MallatZ, and AndrésV: Disruption of the CCL1-CCR8 axis inhibits vascular Treg recruitment and function and promotes atherosclerosis in mice. J Mol Cell Cardiol, 2019; 132:154–163.
32.
HaqueNS, FallonJT, PanJJ, TaubmanMB, and HarpelPC: Chemokine receptor-8 (CCR8) mediates human vascular smooth muscle cell chemotaxis and metalloproteinase-2 secretion. Blood, 2004; 103:1296–1304.
33.
HaqueNS, FallonJT, TaubmanMB, and HarpelPC: The chemokine receptor CCR8 mediates human endothelial cell chemotaxis induced by I-309 and Kaposi sarcoma herpesvirus-encoded vMIP-I and by lipoprotein(a)-stimulated endothelial cell conditioned medium. Blood, 2001; 97:39–45.
SayamaY, KanekoMK, TakeiJ, HosonoH, SanoM, AsanoT, and KatoY: Establishment of a novel anti-TROP2 monoclonal antibody TrMab-29 for immunohistochemical analysis. Biochem Biophys Rep, 2021; 25:100902.
36.
FurusawaY, KanekoMK, and KatoY: Establishment of an Anti-CD20 Monoclonal Antibody (C(20)Mab-60) for Immunohistochemical Analyses. Monoclon Antib Immunodiagn Immunother, 2020; 39:112–116.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
